CN1615931A - Anqi preparation - Google Patents
Anqi preparation Download PDFInfo
- Publication number
- CN1615931A CN1615931A CNA2003101162522A CN200310116252A CN1615931A CN 1615931 A CN1615931 A CN 1615931A CN A2003101162522 A CNA2003101162522 A CN A2003101162522A CN 200310116252 A CN200310116252 A CN 200310116252A CN 1615931 A CN1615931 A CN 1615931A
- Authority
- CN
- China
- Prior art keywords
- preparation
- ammonia
- liquid
- hours
- fructus lycii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 241000382353 Pupa Species 0.000 claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000004321 preservation Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- 235000019628 coolness Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 31
- 239000008280 blood Substances 0.000 abstract description 31
- 239000000463 material Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 241000255789 Bombyx mori Species 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000000050 nutritive effect Effects 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 98
- 229910021529 ammonia Inorganic materials 0.000 description 49
- 230000036541 health Effects 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 37
- 239000003814 drug Substances 0.000 description 18
- 230000037396 body weight Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101162522A CN1274339C (en) | 2003-11-14 | 2003-11-14 | Anqi preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101162522A CN1274339C (en) | 2003-11-14 | 2003-11-14 | Anqi preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1615931A true CN1615931A (en) | 2005-05-18 |
CN1274339C CN1274339C (en) | 2006-09-13 |
Family
ID=34760620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101162522A Expired - Lifetime CN1274339C (en) | 2003-11-14 | 2003-11-14 | Anqi preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1274339C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106072667A (en) * | 2016-06-20 | 2016-11-09 | 陆锦满 | A kind of silkworm chrysalis polypeptide health-preserving paste |
-
2003
- 2003-11-14 CN CNB2003101162522A patent/CN1274339C/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106072667A (en) * | 2016-06-20 | 2016-11-09 | 陆锦满 | A kind of silkworm chrysalis polypeptide health-preserving paste |
Also Published As
Publication number | Publication date |
---|---|
CN1274339C (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1301666C (en) | Health food capable of raising immunity and its production process | |
CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
CN1814167A (en) | Health-care for diabetes | |
CN102613453B (en) | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application | |
CN1305405C (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
CN107343889A (en) | A kind of peacilomyce hepiahi bacterium fermentation culture medium for being used to treat the 1st type or diabetes B | |
CN1726929A (en) | Compsn. of medication for treating diabetes | |
CN1341444A (en) | Health-care product with function of regulating blood sugar and its preparation method | |
CN1225252C (en) | Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof | |
CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
CN1136931A (en) | Ant ginseng oral liquid and preparing process thereof | |
CN1051714C (en) | Traditional Chinese patent medicine for strengthening spleen and appetizing and its preparation method | |
CN103655599A (en) | Polysaccharide composition, application and medicinal preparation containing same | |
CN1256124C (en) | Blood-supplementing medicine composition | |
CN1065753C (en) | Hypoglycemic instant powder and prepn. method | |
CN1831015A (en) | Process for extracting fructus ligustri lucidi and Radixa stragali polysaccharide, the products and application thereof | |
CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
CN1274339C (en) | Anqi preparation | |
CN100350940C (en) | Medicine for treating diabetes and its complications and its preparing process | |
CN1682780A (en) | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method | |
CN1233377C (en) | Fat reducing Chinese drugs for treating simple obesity | |
CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
CN102198174B (en) | Traditional Chinese medicine formulated preparation for nourishing kidney, removing heat from liver, reducing sugar and regulating fat, and preparation method thereof | |
CN1201774C (en) | Medicine for treat hyperlipemia | |
CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: XINJIANG QIKANG HABO UIGUR MEDICINE CO., LTD. Free format text: FORMER NAME: QIKANGHABO UYGUR MEDICINE CO., LTD., XINJIANG |
|
CP03 | Change of name, title or address |
Address after: 830026 No. 625 Yingbin Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee after: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. Address before: 830001 No. 36, Yanan Road, Urumqi, the Xinjiang Uygur Autonomous Region Patentee before: QIKANGHABO UGGR MEDICINE Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 830000 the Xinjiang Uygur Autonomous Region Urumqi hi tech Industrial Development Zone (new urban area) 1375 Patentee after: New Qikang Pharmaceutical Co.,Ltd. Address before: 830026 Yingbin Road, Urumqi, the Xinjiang Uygur Autonomous Region 625 Patentee before: XINJIANG QIKANG HABO UIGHUR MEDICINE CO.,LTD. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term |
Granted publication date: 20060913 |
|
CX01 | Expiry of patent term |